Update Note
Delayed orders weigh on results - Q3 update
Jakob Söderblom
Marcus Develius
2026-10-21
07:09 CEST
Qualisys pre-announced weaker-than-expected Q3 results on 20 October. Net sales are expected at cSEK46m, down 15% Y/Y from SEK54.3m and c25% below our SEK61.7m estimate. EBIT is expected at cSEK0.2m versus SEK8.0m in Q3 2025 and our SEK7.2m estimate. This implies an EBIT margin of 0.4%, down from 14.7% last year and our 11.7% forecast. We lower our fair value range to SEK57–72 (59–75).
Weak Q3, mainly due to delayed orders. Postponed orders in US Life Science and EMEA weighed on sales, while EBIT was further pressured by markerless commercialisation costs being incurred on a lower revenue base. We view this as primarily an order-timing issue and still expect Q4 to be a strong quarter, with a significant part of the delayed orders expected to convert into revenue during the quarter.
We reduce 2026–28e net sales and adj. EBIT by 2–4%. The estimate cuts reflect a weaker Q3 and we also pencil in a slightly more cautious recovery profile.
Fair value range lowered to SEK57–72. We continue to value Qualisys on 2027e earnings, but cut our fair value range to SEK57–72 following the preliminary Q3 figures. The range corresponds to an unchanged 10–13x 2027e EV/EBIT, as we view the miss as mainly reflecting delayed rather than lost orders. The shares are trading slightly below the peer average of c14x, excluding Net Insight, and a recovery in volumes would still provide meaningful operating leverage, in our view.